Plasma biomarkers increase diagnostic confidence in patients with Alzheimer’s disease or frontotemporal lobar degeneration

[1]  J. Molinuevo,et al.  Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients , 2023, JAMA neurology.

[2]  K. Blennow,et al.  Plasma biomarkers for Alzheimer’s disease: a field-test in a memory clinic , 2023, Journal of Neurology, Neurosurgery, and Psychiatry.

[3]  Sterling C. Johnson,et al.  Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring , 2022, Nature Medicine.

[4]  K. Blennow,et al.  Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[5]  K. Blennow,et al.  Classification accuracy of blood-based and neurophysiological markers in the differential diagnosis of Alzheimer’s disease and frontotemporal lobar degeneration , 2022, Alzheimer's Research & Therapy.

[6]  K. Blennow,et al.  Clinical performance and robustness evaluation of plasma amyloid‐β42/40 prescreening , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[7]  K. Blennow,et al.  Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease , 2022, Nature Medicine.

[8]  G. Frisoni,et al.  The Clinical Use of Alzheimer’s Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer’s Disease Consortium Survey , 2022, Journal of Alzheimer's disease : JAD.

[9]  K. Blennow,et al.  Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5–90 years , 2022, Brain communications.

[10]  K. Blennow,et al.  The accuracy and robustness of plasma biomarker models for amyloid PET positivity , 2022, Alzheimer's research & therapy.

[11]  A. Nordberg,et al.  Reactive astrogliosis: A friend or foe in the pathogenesis of Alzheimer’s disease , 2021, Journal of neurochemistry.

[12]  K. Blennow,et al.  The probabilistic model of Alzheimer disease: the amyloid hypothesis revised , 2021, Nature Reviews Neuroscience.

[13]  W. Flier,et al.  Blood-based biomarkers for Alzheimer's disease: towards clinical implementation , 2021, The Lancet Neurology.

[14]  W. M. van der Flier,et al.  Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services—part 1 of 6 , 2021, Alzheimer's research & therapy.

[15]  K. Blennow,et al.  Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease , 2021, Brain : a journal of neurology.

[16]  P. Svenningsson,et al.  A multicentre validation study of the diagnostic value of plasma neurofilament light , 2021, Nature Communications.

[17]  K. Blennow,et al.  Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology , 2021, Acta Neuropathologica.

[18]  K. Blennow,et al.  Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration. , 2020, Journal of Alzheimer's disease : JAD.

[19]  K. Blennow,et al.  Diagnostic and prognostic value of serum NfL and p-Tau181 in frontotemporal lobar degeneration , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.

[20]  G. Farrar,et al.  Initial Physician Experience with [18F]Flutemetamol Amyloid PET Imaging Following Availability for Routine Clinical Use in Japan , 2020, Journal of Alzheimer's disease reports.

[21]  K. Blennow,et al.  Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts , 2020, The Lancet Neurology.

[22]  James G. Bollinger,et al.  High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis , 2019, Neurology.

[23]  W. M. van der Flier,et al.  Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project , 2018, JAMA neurology.

[24]  M. Mintun,et al.  Effectiveness of Florbetapir PET Imaging in Changing Patient Management , 2017, Dementia and Geriatric Cognitive Disorders.

[25]  Murray Grossman,et al.  Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria , 2017, Movement disorders : official journal of the Movement Disorder Society.

[26]  W. M. van der Flier,et al.  Diagnostic impact of [18F]flutemetamol PET in early-onset dementia , 2017, Alzheimer's Research & Therapy.

[27]  P. Scheltens,et al.  Impact of molecular imaging on the diagnostic process in a memory clinic , 2013, Alzheimer's & Dementia.

[28]  Mark Hallett,et al.  Criteria for the diagnosis of corticobasal degeneration , 2013, Neurology.

[29]  M. Prince,et al.  Epidemiology of dementias and Alzheimer's disease. , 2012, Archives of medical research.

[30]  Nick C Fox,et al.  Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. , 2011, Brain : a journal of neurology.

[31]  J. Hodges,et al.  Motor neuron dysfunction in frontotemporal dementia. , 2011, Brain : a journal of neurology.

[32]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[33]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[34]  B. Miller,et al.  Classification of primary progressive aphasia and its variants , 2011, Neurology.

[35]  Bruce L. Miller,et al.  Frontotemporal lobar degeneration , 2010, CNS drugs.

[36]  Catherine Lomen-Hoerth,et al.  The overlap of amyotrophic lateral sclerosis and frontotemporal dementia , 2002, Neurology.